Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Generics UK

Roche Basel Switzerland

Roche gets EU green light for Cotellic

Approved in combination with Zelboraf for melanoma

Gilead Sciences

Gilead’s HIV drug Genvoya cleared in EU

First TAF-based regimen to be approved in the US and EU

Biogen Idec building

Biogen and Sobi’s Elocta wins EU approval

First haemophilia A treatment to offer prolonged protection against bleeding

- PMLiVE

Amgen’s Kyprolis approved in Europe

Multiple myeloma drugwins licence three years after gaining US approval

EU flag

Celgene’s Vidaza wins wider approval for acute myeloid leukaemia

Elderly patients to gain access to cancer drug

- PMLiVE

Lundbeck sways NICE with new Brintellix data

Final draft guidance now backs the major depressive disorder drug

- PMLiVE

Europe’s health information systems to be modernised

Joint EC-WHO work will form a major strand of their renewedcollaboration

- PMLiVE

New EC health director general takes office

XavierPrats Monné will report to health commissioner Dr Vytenis Andriukaitis

- PMLiVE

Lundbeck to cut 1,000 jobs in major restructure

Losses will be felt in its headquarter functions and commercial operations

- PMLiVE

EU green light for Novartis’ skin cancer therapy

Swiss firm’s basal cell carcinoma treatment can now be launched across Europe

- PMLiVE

US filing aims to elevate Brintellix above its competition

Drug looking for an edge in the highly competitive major depressive disorder market

Boehringer Ingelheim headquarters

Hikma pays $2.6bn for Boehringer’s US generics unit

Follows Teva’s $40.5bn purchase of Allgeran’s generics business earlier this week

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links